These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 24361480)

  • 21. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
    Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
    Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Lu G; Nie W; Xin M; Meng Y; Gu J; Miao H; Cheng X; Chan ASC; Zou Y
    Eur J Med Chem; 2022 Dec; 243():114790. PubMed ID: 36183505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
    Tian Y; Xie Z; Liao C
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors.
    Scarpelli R; Boueres JK; Cerretani M; Ferrigno F; Ontoria JM; Rowley M; Schultz-Fademrecht C; Toniatti C; Jones P
    Bioorg Med Chem Lett; 2010 Jan; 20(2):488-92. PubMed ID: 20007017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
    Zhu G; Myint M; Ang WH; Song L; Lippard SJ
    Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of proliferation and invasiveness of ovarian cancer C13* cells by a poly(ADP-ribose) polymerase inhibitor and the role of nuclear factor-κB.
    Wang Z; Li Y; Lv S; Tian Y
    J Int Med Res; 2013 Oct; 41(5):1577-85. PubMed ID: 24097829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
    Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
    J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
    Canan Koch SS; Thoresen LH; Tikhe JG; Maegley KA; Almassy RJ; Li J; Yu XH; Zook SE; Kumpf RA; Zhang C; Boritzki TJ; Mansour RN; Zhang KE; Ekker A; Calabrese CR; Curtin NJ; Kyle S; Thomas HD; Wang LZ; Calvert AH; Golding BT; Griffin RJ; Newell DR; Webber SE; Hostomsky Z
    J Med Chem; 2002 Nov; 45(23):4961-74. PubMed ID: 12408707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP inhibitors for anticancer therapy.
    Curtin N
    Biochem Soc Trans; 2014 Feb; 42(1):82-8. PubMed ID: 24450632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations.
    Alano CC; Kauppinen TM; Valls AV; Swanson RA
    Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9685-90. PubMed ID: 16769901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
    Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
    Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC; Moore KN
    Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
    Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
    Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
    Mégnin-Chanet F; Bollet MA; Hall J
    Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.